RT @SMImmunology: An interesting case report by @RandySweisMD and @jasonlukemd Pseudoprogression manifesting as recurrent ascites with anti…
RT @SMImmunology: An interesting case report by @RandySweisMD and @jasonlukemd Pseudoprogression manifesting as recurrent ascites with anti…
RT @SMImmunology: An interesting case report by @RandySweisMD and @jasonlukemd Pseudoprogression manifesting as recurrent ascites with anti…
An interesting case report by @RandySweisMD and @jasonlukemd Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer https://t.co/JMzy8tINzf
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @sitcancer: #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder can…
#JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer https://t.co/j2uodR61jz https://t.co/1vZ1t4HvgU
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @sitcancer: #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder can…
#JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer https://t.co/j2uodR61jz https://t.co/vg17EsH3Aj
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
RT @Dr_RaviMadan: Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinica…
Words of caution from the authors which I would loudly echo given the clinical ramifications of a poor decision: "Clinical judgment remains key... for an individual patient since #pseudoprogression is far less common in general than actual disease progress
RT @sitcancer: #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder can…
RT @sitcancer: #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder can…
#JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer https://t.co/j2uodR61jz https://t.co/PkGku0DuNi
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. https://t.co/5VBI8Yiw0v
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @sitcancer: New #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder…
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @sitcancer: New #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder…
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @sitcancer: New #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder…
RT @RandySweisMD: Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed…
RT @sitcancer: New #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder…
Check out our case report: A metastatic urothelial #bladdercancer patient treated with anti-PD-1 #immunotherapy developed recurrent ascites due to a massive influx of activated T lymphocytes and a clinical partial response with regression peritoneal nodule
RT @sitcancer: New #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder…
New #JITC case report: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer https://t.co/j2uodR61jz https://t.co/1Emf2iQe5E